Ablynx to Present at 2013 J.P. Morgan Healthcare Conference
GHENT, BELGIUM -- (Marketwire) -- 01/07/13 -- Ablynx (EURONEXT
BRUSSELS: ABLX) today announces it will present at the 31st Annual
J.P. Morgan Healthcare Conference in San Francisco, California on
Thursday, 10th January 2013 at 12:00 p.m. PST (21:00 p.m. CET).
The presentation, followed by a Q&A, will be hosted by Dr Edwin
Moses, CEO and Chairman of Ablynx. The presentation will provide an
update on the Company's late-stage proprietary Nanobody(R)
programmes, the Company's growth and partnering strategy and the
outlook for the near term future.
The presentation will be webcast live and can be accessed on the day
via the Ablynx website at www.ablynx.com. A replay of the webcast
will be available on the Company's website for 30 days following the
presentation. To ensure a timely connection, it is recommended that
users register at least 10 minutes prior to the scheduled webcast.
Ablynx is a biopharmaceutical company engaged in the
discovery and development of Nanobodies(R), a novel class of
therapeutic proteins based on single-domain antibody fragments, for a
range of serious human diseases, including inflammation, haematology,
oncology and pulmonary disease. Today, the Company has approximately
25 programmes in the pipeline and five Nanobodies at clinical
development stage. Ablynx has ongoing research collaborations and
significant partnerships with major pharmaceutical companies
including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co.
The Company is headquartered in Ghent, Belgium.
More information can be found on www.ablynx.com.
press release in pdf format:
For more information, please contact
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193
+32 (0)473 39 50 68
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
Follow us on Twitter @AblynxABLX
t: +44 207 920 2330
Press spacebar to pause and continue. Press esc to stop.